Richard van Breemen, a researcher at Oregon State’s Global Hemp Innovation Center, College of Pharmacy, and Linus Pauling Institute, said preclinical trials consist of using animal models and cell cultures to determine the safety and effectiveness of promising drug candidates.
“We need preclinical trials to prove the efficacy of what we discovered, and I think that will happen very soon, in the next few months,” van Breemen said.
On Jan. 10, van Breemen and his team published a study stating that cannabigerolic acid and cannabidiolic acid, compounds within hemp, bond with the SARS-CoV-2 spike protein and block a critical part of the process that allows the coronavirus to infect individuals.
“These cannabinoid acids are abundant in hemp and in many hemp extracts,” van Breemen said.
“They are not controlled substances like THC, the psychoactive ingredient in marijuana, and have a good safety profile in humans. And our research showed the hemp compounds were equally effective against variants of SARS-CoV-2, including variant B.1.1.7, which was first detected in the United Kingdom, and variant B.1.351, first detected in South Africa.”
Natural products like cannabis are a common source for prescription medicines, van Breemen said.
“We’ve been interested in natural products and sources of new therapeutic agents for a very long time,” he said.
“Hemp is particularly interesting because it is a rich source of unique natural products. We’ve probably only investigated 10% of the natural products that nature provides to us, so there are many more molecules to be discovered and many more investigations to be carried out, to find out which diseases or types of infections these molecules might be helpful in preventing or treating.”
This article was originally published by Washington Examiner. Read the original article.
ThinkCivics researches, examines, and reports on issues that matter most. We deliver explanative, fearless, and insightful analysis for public consumption.
